Journal
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Volume 107, Issue 43, Pages 18392-18397Publisher
NATL ACAD SCIENCES
DOI: 10.1073/pnas.1012539107
Keywords
microfluidics; ctcs; prostate cancer; clusters; point-of-care
Categories
Funding
- Prostate Cancer Foundation
- National Institute for Biomedical Imaging and Bioengineering
- National Institutes of Health/National Cancer Institute (NIH)/(NCI) [CA89138]
- Ellison Foundation
- AstraZeneca
- Martell Foundation
- Alex and Sonja Spier
- Monell Foundation
- American Cancer Society New England Division
- NIH
- Department of Defense
- American Society of Clinical Oncology (ASCO) Cancer Foundation
- Howard Hughes Medical Institute
Ask authors/readers for more resources
Rare circulating tumor cells (CTCs) present in the bloodstream of patients with cancer provide a potentially accessible source for detection, characterization, and monitoring of nonhematological cancers. We previously demonstrated the effectiveness of a microfluidic device, the CTC-Chip, in capturing these epithelial cell adhesion molecule (EpCAM)-expressing cells using antibody-coated microposts. Here, we describe a high-throughput microfluidic mixing device, the herringbone-chip, or HB-Chip, which provides an enhanced platform for CTC isolation. The HB-Chip design applies passive mixing of blood cells through the generation of microvortices to significantly increase the number of interactions between target CTCs and the antibody-coated chip surface. Efficient cell capture was validated using defined numbers of cancer cells spiked into control blood, and clinical utility was demonstrated in specimens from patients with prostate cancer. CTCs were detected in 14 of 15 (93%) patients with metastatic disease (median 63 CTCs/mL, mean = 386 +/- 238 CTCs/mL), and the tumor-specific TMPRSS2-ERG translocation was readily identified following RNA isolation and RT-PCR analysis. The use of transparent materials allowed for imaging of the captured CTCs using standard clinical histopathological stains, in addition to immunofluorescence-conjugated antibodies. In a subset of patient samples, the low shear design of the HB-Chip revealed microclusters of CTCs, previously unappreciated tumor cell aggregates that may contribute to the hematogenous dissemination of cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available